Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial

Peer Review reports

Original Submission
24 Aug 2022	Submitted	Original manuscript
10 Nov 2022	Reviewed	Reviewer Report - Man Han
1 Dec 2022	Reviewed	Reviewer Report - Alexander Gough
31 Jan 2023	Author responded	Author comments - Toshimasa Shimizu
Resubmission - Version 2
31 Jan 2023	Submitted	Manuscript version 2
13 Feb 2023	Reviewed	Reviewer Report - Alexander Gough
15 Feb 2023	Reviewed	Reviewer Report - Man Han
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
16 Feb 2023	Editorially accepted
3 Mar 2023	Article published	10.1186/s13063-023-07176-5

Back to article page